Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Heptares, Cubist Join On GPCR Research
by Rick Mullin
January 14, 2013
| A version of this story appeared in
Volume 91, Issue 2
Heptares Therapeutics and Cubist Pharmaceuticals will collaborate on the discovery of new therapies targeting G protein-coupled receptors (GPCRs) using Heptares’ drug discovery platform. Under the agreement, Cubist will hold exclusive worldwide rights to develop and commercialize drug candidates identified by the partners. Cubist will pay Heptares $5.5 million up front and up to $4 million in research funding, plus milestones and royalties, for the first drug target. GPCRs are membrane proteins involved in a broad range of biological processes and diseases.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter